The Urgent Need for New Vaccines

 

Fighting an Epidemic

TB vaccine research lab - Aurum Institute, Tembisa, South Africa

Tuberculosis (TB) kills more people than any other single infectious disease agent in the world, causing 10.4 million illnesses and taking 1.7 million lives in 2016. It’s a shocking milestone.

Because TB is an airborne disease, people often say “TB anywhere is TB everywhere.” The threat of drug-resistant TB adds another layer of concern. Treatment for TB is long, expensive, and has some nasty side effects. And after treatment, it is possible to get TB again. And again.

The existing TB vaccine, BCG, is now almost 100 years old and is only moderately effective in preventing severe TB in infants and young children. It works even less well in adolescents and adults, who are most at risk for developing and spreading TB, and has failed to halt the TB epidemic.

It doesn’t have to be this way. We can and must do better.

New Tools are Critical

New tools – drugs, diagnostics and vaccines – are critical to end the threat of TB. Vaccines are game-changing innovations, helping to stop other deadly diseases, such as smallpox and polio. TB can be next.

TB research lab - KEMRI CDC - Kisumu, Kenya

Aeras is a nonprofit organization developing new, effective TB vaccines that are affordable and accessible to all who need them. We work through partnerships around the world to advance TB vaccine development.

We Need Your Support

To continue this work, Aeras needs your support! Your donation can help! Join our email list to learn about advances in the TB vaccine field. Get involved as a TB advocate. Follow us on Facebook and Twitter to stay up-to-date on the global state of tuberculosis and vaccine development.

Donate

Be a TB Advocate